Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-06
2007-11-06
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C514S114000, C514S119000, C514S317000, C514S326000, C514S330000, C514S365000, C514S400000, C514S422000, C514S423000, C514S576000, C514S578000, C514S579000, C514S665000
Reexamination Certificate
active
10916176
ABSTRACT:
The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis and to an inflammatory reaction magnifying the damage, by the isolated or joint effect of inhibitors of the alanyl amino peptidase (APN) and of the dipeptidyl peptidase N (DP IV). Our results show that the application of inhibitors of the above-referenced enzymes or of preparations and dosage forms containing such inhibitors is definitely suitable for a therapy and prevention of dementia diseases and conditions.
REFERENCES:
patent: 5543396 (1996-08-01), Powers et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 2003/0148961 (2003-08-01), Heiser et al.
patent: 2004/0147434 (2004-07-01), Ansorge et al.
patent: 101 00 053 (2002-08-01), None
patent: WO93/07872 (1993-04-01), None
patent: WO95/34538 (1995-12-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/54707 (2001-08-01), None
patent: WO 02/053169 (2002-07-01), None
patent: WO 2004/064866 (2004-05-01), None
The Merck Index Results, Monograph No.: 09842. Title: Ubenimex. 2006.
Tanaka et al. Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology. 1998, vol. 40, pp. 21-26.
Wu Young—Qian et al “Neuroprotective effects of inhibitors . . . ”, Dipeptidyl Aminopeptides in Health and Disease, Hildebrandt et al, eds. Kluwer Academic, NY, 2003.
Kryzhanovskii G.N. et al. “Effects of Intranasally Administered Substance P . . . ”, XP 002298708 2003, Abstract of Biulleten Eksperimentalnoi Biologii I Meditsiny, vol. 113, pp. 16-19 (Jan. 1992).
Gabrilovac, Jelka et al., “Expression of CD 13/Amino-peptidase N . . . ” Immunology Letters, 2004 vol. 91, pp. 39-47.
Aoyagi Takaaki et al., “Enzymatic Changes In Cerebrospinal Fluid . . . ”, Journal of Clinical Biochemistry And Nutrition 1993, vol. 14, pp. 133-139.
Lendeckel Uwe et al., “Synergistic Action of DPIV and APN . . . ”, XP001183828 2003 Dipeptidyl Aminopeptidases in Health and Disease, Hildebrandt et al, Kluwer Academic, NY, 2003, pp. 123-131.
Database WPI, XP002298709 2004, Abstract of WO 2004/064866 (Aug. 5, 2004).
International Preliminary Report on Patentability (Chapter II), Dec. 8, 2004.
Mosimann; Clincial Presentation and Differential Diagnosis of Dementia with Lewy Bodies and Parkinson's Disease Dementia: Schweiz Med Forum 2005; 5:891-896.
Mack Till
Rohnert Peter
Striggow Frank
Hodgson & Russ LLP
Keyneurotek AG
Russel Jeffrey Edwin
LandOfFree
Use of inhibitors of enzymes having activities of amino... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of enzymes having activities of amino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of enzymes having activities of amino... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874888